{
  "id": 15160602,
  "title": "Beta bionics CCO Mark Hopman sells $13,446 in shares",
  "url": "https://urgent.news/2026/10/17/beta-bionics-cco-mark-hopman-sells-13-446-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-17T08:30:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/beta-bionics-cco-mark-hopman-sells-13446-in-shares-93CH-4955337"
  },
  "original_language": "en",
  "account": null,
  "summary": "Beta Bionics Inc. (NASDAQ:BBNX) saw its Chief Commercial Officer, Mark Hopman, sell 775 shares of the company's common stock on October 14, 2026. The sale, which occurred in accordance with a pre-arranged Rule 10b5-1 plan, resulted in a total value of $13,446 and was executed at prices ranging from $17.35 to $18.3499 per share. Following the transaction, Hopman's beneficial ownership of Beta Bionics common stock decreased to 55,334 shares. The company's stock has seen a week-over-week decline of 7.3%, although it has gained nearly 26% over the past six months. Despite this recent sale, Beta Bionics recently received FDA clearance for its Mint patch pump, a device that integrates with continuous glucose monitors and offers smartphone control. This milestone was met while the company revised its fiscal 2026 revenue guidance downward. The news of the FDA clearance has garnered attention from analysts, with UBS raising its price target for Beta Bionics from $22.00 to $25.00 and maintaining a Buy rating. Other firms, such as Jefferies and Wells Fargo, have also initiated coverage with Buy and Overweight ratings, respectively, citing the company's insulin pump technology and upcoming product launches as key growth drivers.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}